SCHOTT’s Asian Pharmaceutical Market Position Strengthened
SCHOTT continues to strengthen its position in the Asian pharmaceutical market with the opening of a high-tech facility in India.
As with the existing production plant in the city of Daman, SCHOTT KAISHA, a joint venture in which SCHOTT holds a 50% stake, will run the new production facility, located in Jambusar in the western state of Gujarat. The new plant will allow SCHOTT to increase production by 50%, bringing total annual output to about two billion ampoules, vials, syringes, and cartridges. The new facility will also create 350 additional jobs.
According to various studies, the Indian pharmaceutical industry is growing by 14% to 17% a year, primarily due to strong domestic demand from a rising Indian middle-class seeking better medical care. Thanks to its strong and long-standing partnership with KAISHA, SCHOTT is in an excellent position to profit from the predicted market growth.
Dr Jürgen Sackhoff, head of the pharmaceutical systems business unit at SCHOTT, said: "Our quality-first business philosophy has always been what differentiates SCHOTT AG from other companies. In KAISHA, we found a partner in India who shares this philosophy. Together, this new facility will further enhance our ability to help the Indian pharmaceutical industry hit its growth targets."
Fully automated production meets demanding quality standards
The new plant has 20 production lines for ampoules and 16 lines for vials, all fully automated. In addition to computer-controlled line loading using loading robots, high-performance camera systems perform quality inspections.
Jambusar is the first fully automated production facility on the Indian subcontinent and meets global ISO 15378 standards. This underscores SCHOTT’s commitment to produce worldwide in compliance with the international GMP (Good Manufacturing Practice) standard, which is an important benchmark for the production of high-quality primary pharmaceutical packaging.